Our Most Recent Episode
Dr. Eric Bartee, MD, PhD Medical University of South Carolina Interview Date: November 14 Summary Dr. Eric Bartee, MD, PhD and virologist describes a new virus that seems to be a perfect fit for myeloma therapy, making the stem cell transplant process potentially more effective. A new rabbit virus called the myxoma virus can be used after […]
Calling All Musicians: New Music Contest to Support Myeloma Research!
Our new Songs for Life contest is in full swing to help raise funds for multiple myeloma research. Tell your musical friends and family to donate a song between now and November 15. Winners to be included on the Songs For Life 2015 album with all proceeds benefiting myeloma research. Spread the news today!
Our Next Show
Our Next Show: What do the new IMWG guidelines mean for you? Earlier treatment options for smoldering patients and more with Dr. Vincent Rajkumar, MD, Mayo Clinic
Thursday, November 20, 8 am PST, 9 am MST, 10 am CST, 11 am EST
Call In by Phone to Listen Live: (347) 637-2631 or
The International Myeloma Working Group helps define guidelines that are followed worldwide for myeloma care. These guidelines are now changing. Because myeloma can cause so much damage to bone and other organs, new standards are being put into place that identify myeloma early (even before “CRAB” symptoms) and allow for earlier treatment before the severe damage has taken its toll. Dr. Vincent Rajkumar will help us understand what has changed, how it affects smoldering myeloma patients most significantly and how it changes myeloma treatment worldwide.
Dr. Rajkumar is a Professor of Medicine and Chair of the Myeloma, Amyloidosis, and Dysproteinemia Group at the Mayo Clinic in Rochester, Minnesota. He also chairs the Eastern Cooperative Oncology Group or ECOG Myeloma Committee. He has published more than 500 articles and 350 abstracts, and his career was profiled in the November 26, 2011 issue of The Lancet. He has an extensive research program in the field of plasma cell disorders. He has led numerous phase I, II and III clinical trials investigating the role of new agents in myeloma including the very important randomized trial that led to the approval of thalidomide for myeloma in the US. He also leads several large studies investigating the nature, the prevalence, and progression of various monoclonal gammopathies, including myeloma. His laboratory research has been focused on investigating new agents in myeloma and studying the role of angiogenesis in various plasma cell disorders.
He has been continuously funded as an independent investigator by the National Cancer Institute through R01 grants, serves as an Associate Editor for the Mayo Clinic Proceedings, Section Editor for Multiple Myeloma, and related disorders for the journal, Leukemia, and is an Associate Editor for the European Journal of Hematology. He’s Deputy Editor of Blood Cancer Journal. He received the “Relentless for a Cure” award from the Leukemia and Lymphoma Society in 2010 and an award from the American Society of Clinical Oncology in 2011.
Our Previous Episodes
Digging deeper into high risk myeloma with Dr. Jesús San Miguel, MD, PhD, University of Navarra, Spain
Extending Outcomes with Continuous Myeloma Maintenance: Dr. Antonio Palumbo, MD, University of Torino
Detecting myeloma relapse early - The new Hevylite® test can help with Dr. Stephen Harding of The Binding Site
What's new in MGUS? Very interesting ASCO findings and the diagnostics you need to have as an MGUS patient with Dr. Brendan Weiss, MD
The hopeful discovery of an engineered measles virus for myeloma treatment with Dr. Stephen Russell, MD, PhD
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
A compelling European approach in myeloma care: Collaboration, Referrals and Established Guidelines with Dr. Pieter Sonneveld, MD, PhD, Erasmus MC
Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission
Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the "Valley of Death"
Our Next Show: How does a drug begin as an idea and become an actual myeloma therapy in the clinic? Dr. Craig Crews, Crews Laboratory at Yale University discusses his discovery and development of carfilzomib (Kyprolis)
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases
Myeloma is not a single disease: The illuminating discovery and implications for care with Dr. Michael Kuehl, MD, PhD of the NCI
Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants
Three myeloma themes with Dr. Robert Z. Orlowski of MD Anderson Cancer Center:Immunotherapy, making transplant better and using new small molecules for more convenient myeloma care
Dr. Leif Bergsagel, MD of the Mayo Clinic shares the impact of the MYC translocation in myeloma progression and relapse and a new target that boosts immunity while impacting myeloma cells
Genes that drive myeloma growth and why new discoveries of myeloma's complexities are hopeful with Dr. Jens Lohr, MD of The Broad Institute and Dana Farber Cancer Institute
Dr. Philip McCarthy of Roswell Park Cancer Institute on transplants: best induction therapies, best approaches for high risk and how patients can recover faster
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation) to selectively target only active myeloma cells using the common CD38 protein
Find a multiple myeloma specialist near you. We’ve moved this directory to the www.myelomacrowd.org site.